ID | 1084 |
Name of the vaccine | Shan-5 |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | From 6 weeks |
Description of the vaccine | Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae type b conjugate vaccine. |
Name of the manufacturer | Sanofi Healthcare India Private Limited |
Name of the manufacturing country | India |
Year of manufacture | 2014 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | Seroprotection rate for tetanus(100%). |
Vaccine formulation | White suspension |
Dosage | Three doses of 0.5 ml, at least 4 weeks gap. |
Mechanism of action | Boosts the immune system and produces protective antibodies. |
Route of administration | Intramuscular |
Indications | Immunization against diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenzae type b in infants. |
Export | Marketed by : Sanofi Healthcare India Private Limited |
Approval | Central Drugs Standard Control Organization, India and WHO pre-qualified. |
Adjuvant | Aluminium phosphate |
Repurposing | For diphtheria, Hib, pertussis and hepatitis B. |
Side effects of vaccine | Pain, redness and swelling at injection site, fever, vomiting, crying, drowsiness, loss of appetite and irritability. |
Post vaccination | Vaccinee to be medically supervised for at least 30 minutes after vaccination. |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://extranet.who.int/pqweb/content/shan-5-0 |
Other name | NA |
Additional Links | https://www.1mg.com/drugs/shan-5-vaccine-264976
|